Flagship Ventures Fund V, L.P. 13D and 13G filings for Sigilon Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:36 pm Sale |
2023-12-31 | 13G | Sigilon Therapeutics, Inc. SGTX |
Flagship Ventures Fund V, L.P. | 0 0.000% |
-797,721 (Position Closed) |
Filing |
| 2021-02-16 5:06 pm Purchase |
2020-12-31 | 13G | Sigilon Therapeutics, Inc. SGTX |
Flagship Ventures Fund V, L.P. | 797,721 33.200% |
797,721 (New Position) |
Filing |